Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04630262
Other study ID # DSJ_2019_05
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date May 9, 2022
Est. completion date March 31, 2023

Study information

Verified date April 2023
Source DePuy Orthopaedics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, multi-center, non-randomized, single arm observational study. The primary objective of this clinical investigation is to evaluate functional responder rates with an objective performance criteria (OPC) of 85% as measured by the KOOS questionnaire for the first 225 tibia (CR FB and PS FB combined) implanted with the ATTUNE Cementless FB tray (primary and revision procedures) and will be analyzed when these patients have passed the 1 year preferred post-op window.


Description:

The primary objective of this clinical investigation is to evaluate functional responder rates with an objective performance criteria (OPC) of 85% as measured by the KOOS questionnaire for the first 225 tibia (CR FB and PS FB combined) implanted with the ATTUNE Cementless FB tray (primary and revision procedures) and will be analyzed when these patients have passed the 1 year preferred post-op window. Study success will be determined using the primary TKA (CR FB and PS FB combined) analysis group. The secondary objectives of this study are to establish the surgical effectiveness of the ATTUNE Cementless Tibial Base by evaluating type and frequency of Adverse Events and Device Deficiencies, functional responder rates with an objective performance criteria (OPC) of 85% as measured by the KOOS questionnaire for all subjects (CR FB and PS FB combined) at the 1-year timepoint, the change from preoperative baseline to the 6-week, 6-month, 1-year, 2-year and 5-year timepoints in functional outcomes and quality of life assessments, as measured using additional patient reported outcomes measures (PROMS), implant survivorship of the ATTUNE Cementless FB Tibial base using Kaplan-Meier survival analysis at 1, 2 and 5-year timepoints, and investigator-conducted radiographic analysis of the tibial and patellar components at 6 weeks/6 months 1, 2 and 5 years after surgery.


Recruitment information / eligibility

Status Terminated
Enrollment 34
Est. completion date March 31, 2023
Est. primary completion date March 31, 2023
Accepts healthy volunteers No
Gender All
Age group 22 Years to 80 Years
Eligibility Inclusion Criteria: 1. Subject is male or female and between the ages of 22 and 80 years at the time of consent, inclusive. 2. Subject has a severely painful knee and/or impaired knee function resulting from osteoarthritis, post-traumatic arthritis, or a failed previous implant provided that adequate bone is present. 3. Subject that is willing to give voluntary, written informed consent to participate in this clinical investigation and authorize the transfer of his/her information to the Sponsor. 4. Subject is currently not bedridden. 5. Subject, in the opinion of the Investigator, is able to understand this clinical investigation and is willing and able to perform all study procedures and follow-up visits and co-operate with investigational procedures. 6. Subject is able to read and comprehend the Informed Consent Document as well as complete the required PROMs in either English or one of the available translations. Exclusion Criteria: - a) The Subject is a woman who is pregnant or lactating. b) Contralateral knee has already been enrolled in this study . c) Revision knee that was previously enrolled in the study as a primary knee (ipsilateral). d) Subject has participated in a clinical study with an investigational product (drug or device) in the last two (2) years. e) Subject has had surgery on their contralateral knee within six (6) months of study enrolment or has surgery planned on their contralateral knee less than six (6) months of the study surgery. f) Subject is suffering from inflammatory arthritis in any joint (e.g., rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, etc.). g) Active local or systemic infection. h) Loss of bone or musculature, inadequate bone quality (e.g. severe osteoporosis), neuromuscular compromise or vascular deficiency at the bone site in the affected limb in sufficient degree to render the procedure unjustifiable (e.g. absence of musculoligamentous supporting structures that could lead to implant instability, joint neuropathy). i) Severe instability secondary to advanced loss of osteochondral structure or the absence of collateral ligament integrity. j) The inability to make bone cuts (e.g. inadequate bone stock) so as to assure correct component position, a firm press fit, and intimate apposition of the cut bone and prosthetic surfaces. k) Subject is currently involved in any personal injury litigation, medical-legal or worker's compensation claims. l) Subject, in the opinion of the Investigator, is a drug or alcohol abuser (in the last five 5 years) or has a psychological disorder that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.

Study Design


Intervention

Device:
ATTUNE Cementless CR Fixed Bearing
Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and CR or (Medial Stabilized) MS Tibial Insert.
ATTUNE Cementless PS Fixed Bearing
Subjects Implanted with the ATTUNE Cementless Femoral, Cementless Tibia, and PS Tibial Insert.

Locations

Country Name City State
United States Anderson Clinic Alexandria Virginia
United States Johns Hopkins Orthpaedic Surgery Baltimore Maryland
United States Rubin Institute for Advanced Orthopedics Baltimore Maryland
United States Towson Orthopaedic Associates Baltimore Maryland
United States Coastal Orthopedics Bradenton Florida
United States American Hip Institute & Orthopedic Specialists Chicago Illinois
United States University of Missouri Columbia Missouri
United States Florida Orthopaedic Associates DeLand Florida
United States University of Florida Gainesville Florida
United States Orlin & Cohen Orthopedics Garden City New York
United States Orthopaedic Associates of Michigan Grand Rapids Michigan
United States Orthopaedic Specialty Institute Irvine California
United States Loyola University Medical Center Maywood Illinois
United States Mercy Clinic Springfield Ozark Missouri
United States University Orthopaedic Associates, LLC Somerset New Jersey

Sponsors (1)

Lead Sponsor Collaborator
DePuy Orthopaedics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Functional Responder Rate of first 225 Subjects A functional responder is defined as a subject that shows at least 20% improvement in Knee Injury and Osteoarthritis Outcome Score (KOOS) from baseline and at least a 10 point improvement in at least two of the following: KOOS Activities of Daily Living, KOOS Pain, and KOOS Quality of Life. The maximum total score is 100 indicating no symptoms and the minimum is 0 indicating extreme symptoms. 1 Year
Secondary Type of Adverse Events An Adverse Event (AE) is Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to a medical device. This measure will assess the type of AEs reported throughout the duration of the study. Through study completion or 5 years.
Secondary Frequency of Adverse Events An Adverse Event (AE) is Any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to a medical device. This measure will assess the frequency of AEs reported throughout the duration of the study. Through study completion or 5 years.
Secondary Type of Device Deficiencies A Device Deficiency (DD) is inadequacy of a medical device related to its identity, quality, durability, reliability, safety or performance, such as malfunction, misuse, use error or inadequacy in information supplied by the manufacturer. This measure will assess the type of DDs reported throughout the duration of the study. Through study completion or 5 years.
Secondary Frequency of Device Deficiencies A Device Deficiency (DD) is inadequacy of a medical device related to its identity, quality, durability, reliability, safety or performance, such as malfunction, misuse, use error or inadequacy in information supplied by the manufacturer. This measure will assess the frequency of DDs reported throughout the duration of the study. Through study completion or 5 years.
Secondary Functional Responder Rate All Subjects A functional responder is defined as a subject that shows at least 20% improvement in Knee Injury and Osteoarthritis Outcome Score (KOOS) from baseline and at least a 10 point improvement in at least two of the following: KOOS Activities of Daily Living, KOOS Pain, and KOOS Quality of Life. The maximum total score is 100 indicating no symptoms and the minimum is 0 indicating extreme symptoms. 1 Year
Secondary Kaplan-Meier Implant Survivorship Number/rate of subjects with all implants remaining implanted at the 1 year timepoint. 1 Year
Secondary Kaplan-Meier Implant Survivorship Number/rate of subjects with all implants remaining implanted at the 2 year timepoint. 2 Years
Secondary Kaplan-Meier Implant Survivorship Number/rate of subjects with all implants remaining implanted at the 5 year timepoint. 5 Years
Secondary Knee Society Score Mixed outcome measure that derives a score using physician input and patient input including current symptoms, knee function, patient satisfaction and expectations. The higher the score, the better the function, satisfaction, and expectations. The max score can be greater than 100 and the min score can be less than 0. 6 weeks
Secondary Knee Society Score Mixed outcome measure that derives a score using physician input and patient input including current symptoms, knee function, patient satisfaction and expectations. The higher the score, the better the function, satisfaction, and expectations. The max score can be greater than 100 and the min score can be less than 0. 6 months
Secondary Knee Society Score Mixed outcome measure that derives a score using physician input and patient input including current symptoms, knee function, patient satisfaction and expectations. The higher the score, the better the function, satisfaction, and expectations. The max score can be greater than 100 and the min score can be less than 0. 1 year
Secondary Knee Society Score Mixed outcome measure that derives a score using physician input and patient input including current symptoms, knee function, patient satisfaction and expectations. The higher the score, the better the function, satisfaction, and expectations. The max score can be greater than 100 and the min score can be less than 0. 2 years
Secondary Knee Society Score Mixed outcome measure that derives a score using physician input and patient input including current symptoms, knee function, patient satisfaction and expectations. The higher the score, the better the function, satisfaction, and expectations. The max score can be greater than 100 and the min score can be less than 0. 5 years
Secondary Knee Injury and Osteoarthritis Outcome Score (KOOS) A knee-specific instrument that derives a score developed to assess the patients' opinion about their knee and associated problems. The maximum total score is 100 indicating no symptoms and the minimum is 0 indicating extreme symptoms. 6 weeks
Secondary Knee Injury and Osteoarthritis Outcome Score (KOOS) A knee-specific instrument that derives a score developed to assess the patients' opinion about their knee and associated problems. The maximum total score is 100 indicating no symptoms and the minimum is 0 indicating extreme symptoms. 6 months
Secondary Knee Injury and Osteoarthritis Outcomes Score (KOOS) A knee-specific instrument that derives a score developed to assess the patients' opinion about their knee and associated problems. The maximum total score is 100 indicating no symptoms and the minimum is 0 indicating extreme symptoms. 1 year
Secondary Knee Injury and Osteoarthritis Outcome Score (KOOS) A knee-specific instrument that derives a score developed to assess the patients' opinion about their knee and associated problems. The maximum total score is 100 indicating no symptoms and the minimum is 0 indicating extreme symptoms. 2 years
Secondary Knee Injury and Osteoarthritis Outcome Score (KOOS) A knee-specific instrument that derives a score developed to assess the patients' opinion about their knee and associated problems. The maximum total score is 100 indicating no symptoms and the minimum is 0 indicating extreme symptoms. 5 years
Secondary Forgotten Joint Score (FJS-12) The Forgotten Joint Scores comprise measures for the assessment of joint-specific patient-reported outcome (PRO). These PRO questionnaires focus on patients' awareness of a specific joint in everyday life. Joint awareness can be simply defined as any unintended perception of a joint. This may include strong sensations like pain, but also includes more subtle feelings like mild stiffness, subjective dysfunction, or any discomfort. The FJS-12 score ranges from 0 to 100, with 0 being the worst score and 100 being the best. A higher score means the patient is better able to forget about the artificial joint in daily life. So, the higher the score, the better the outcome is. 6 weeks
Secondary Forgotten Joint Score (FJS-12) The Forgotten Joint Scores comprise measures for the assessment of joint-specific patient-reported outcome (PRO). These PRO questionnaires focus on patients' awareness of a specific joint in everyday life. Joint awareness can be simply defined as any unintended perception of a joint. This may include strong sensations like pain, but also includes more subtle feelings like mild stiffness, subjective dysfunction, or any discomfort. The FJS-12 score ranges from 0 to 100, with 0 being the worst score and 100 being the best. A higher score means the patient is better able to forget about the artificial joint in daily life. So, the higher the score, the better the outcome is. 6 months
Secondary Forgotten Joint Score (FJS-12) The Forgotten Joint Scores comprise measures for the assessment of joint-specific patient-reported outcome (PRO). These PRO questionnaires focus on patients' awareness of a specific joint in everyday life. Joint awareness can be simply defined as any unintended perception of a joint. This may include strong sensations like pain, but also includes more subtle feelings like mild stiffness, subjective dysfunction, or any discomfort. The FJS-12 score ranges from 0 to 100, with 0 being the worst score and 100 being the best. A higher score means the patient is better able to forget about the artificial joint in daily life. So, the higher the score, the better the outcome is. 1 year
Secondary Forgotten Joint Score (FJS-12) The Forgotten Joint Scores comprise measures for the assessment of joint-specific patient-reported outcome (PRO). These PRO questionnaires focus on patients' awareness of a specific joint in everyday life. Joint awareness can be simply defined as any unintended perception of a joint. This may include strong sensations like pain, but also includes more subtle feelings like mild stiffness, subjective dysfunction, or any discomfort. The FJS-12 score ranges from 0 to 100, with 0 being the worst score and 100 being the best. A higher score means the patient is better able to forget about the artificial joint in daily life. So, the higher the score, the better the outcome is. 2 years
Secondary Forgotten Joint Score (FJS-12) The Forgotten Joint Scores comprise measures for the assessment of joint-specific patient-reported outcome (PRO). These PRO questionnaires focus on patients' awareness of a specific joint in everyday life. Joint awareness can be simply defined as any unintended perception of a joint. This may include strong sensations like pain, but also includes more subtle feelings like mild stiffness, subjective dysfunction, or any discomfort. The FJS-12 score ranges from 0 to 100, with 0 being the worst score and 100 being the best. A higher score means the patient is better able to forget about the artificial joint in daily life. So, the higher the score, the better the outcome is. 5 years
Secondary EuroQol 5-Dimension 5-Level (EQ-5D-5L) The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. Scores are derived by a 5 digit code. The higher the number, the better the overall health status of the patient. 6 weeks
Secondary EuroQol 5-Dimension 5-Level (EQ-5D-5L) The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. Scores are derived by a 5 digit code. The higher the number, the better the overall health status of the patient. 6 months
Secondary EuroQol 5-Dimension 5-Level (EQ-5D-5L) The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. Scores are derived by a 5 digit code. The higher the number, the better the overall health status of the patient. 1 Year
Secondary EuroQol 5-Dimension 5-Level (EQ-5D-5L) The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. Scores are derived by a 5 digit code. The higher the number, the better the overall health status of the patient. 2 Years
Secondary EuroQol 5-Dimension 5-Level (EQ-5D-5L) The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. Scores are derived by a 5 digit code. The higher the number, the better the overall health status of the patient. 5 Years
Secondary Investigator-conducted Radiographic Analysis Rate of radiolucencies and other significant radiographic findings identified by clinical investigators. 6 weeks or 6 months
Secondary Investigator-conducted Radiographic Analysis Rate of radiolucencies and other significant radiographic findings identified by clinical investigators. 1 Year
Secondary Investigator-conducted Radiographic Analysis Rate of radiolucencies and other significant radiographic findings identified by clinical investigators. 2 Years
Secondary Investigator-conducted Radiographic Analysis Rate of radiolucencies and other significant radiographic findings identified by clinical investigators. 5 Years
See also
  Status Clinical Trial Phase
Completed NCT03277066 - A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis Phase 2
Recruiting NCT03090698 - Outcomes of Injections in Patients Waiting for Total Knee Replacement Phase 4
Completed NCT02556710 - A Study to Evaluate the Efficacy & Safety of an Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee Phase 3
Withdrawn NCT02237846 - Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis Phase 1/Phase 2
Completed NCT02242435 - A Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis Phase 3
Completed NCT01849445 - Targeted Rehabilitation to Improve Outcome After Knee Replacement- A Physiotherapy Study N/A
Completed NCT02096393 - Patient Specific Instrumentation in TKR N/A
Completed NCT01704157 - A Prospective Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device N/A
Active, not recruiting NCT01374230 - Long-Term Multicenter Evaluation of the E1® Tibial Bearing N/A
Completed NCT02156440 - Cross-over Study of the Efficacy and Safety of SierraSil Joint Formula 14 in Osteoarthritis of the Knee Phase 2
Completed NCT01410409 - Structured Treatment of Osteoarthritis of the Knee With or Without Total Knee Replacement N/A
Not yet recruiting NCT01270412 - Platelet Rich Plasma (PRP) as a Treatment for Knee Osteoarthritis PRP as a Treatment for Knee Osteoarthritis Phase 2/Phase 3
Completed NCT01207115 - A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee Phase 2
Completed NCT01331278 - A Comparative Study of Knee Systems Phase 4
Completed NCT00970008 - Exploring Massage Benefits for Arthritis of the Knee Phase 2
Completed NCT00988091 - Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee Phase 3
Completed NCT00531427 - Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee Phase 3
Completed NCT00792727 - HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain Phase 3
Completed NCT00449696 - Gel-200 Versus Placebo in Osteoarthritis of the Knee Phase 3
Completed NCT04145011 - Coolief Cooled Radiofrequency vs. Conventional Radiofrequency to Manage OA Knee Pain N/A